Sun-Novo(SH:688621) Ge Long Hui·2025-12-24 09:24Core Viewpoint - The company has entered into a collaboration agreement with Zhejiang Xinghao Holdings for the development of the STC008 injection project, which is currently in Phase I clinical trials [1] Group 1: Financial Aspects - The company will receive an initial payment of RMB 50 million and subsequent milestone payments totaling RMB 500 million (including tax) [1] - The company will also earn an 8% share of the net sales (excluding tax) from the project [1] Group 2: Project Details - STC008 is a self-initiated research project aimed at treating cancer cachexia in patients with advanced solid tumors [1] - The project is currently in the Phase I clinical trial stage, which is characterized by a long and complex approval process influenced by various uncertainties [1] Group 3: Market Considerations - The sales performance of the new drug post-launch will be affected by market conditions and industry developments [1] - The milestone payments outlined in the contract are contingent upon meeting certain conditions, introducing an element of uncertainty regarding their realization [1]